Scientists hunt for clues to cancer drug resistance in 400 patients
NCT ID NCT07259226
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This study enrolls 400 adults with advanced breast, lung, stomach, or bladder cancer who are receiving antibody-drug conjugates (ADCs), a type of targeted therapy. Researchers will compare tumor samples taken before treatment and after the cancer progresses to identify genetic or molecular changes linked to drug resistance. The goal is to better predict which patients will benefit from ADCs and why resistance develops.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy Cancer Center
RECRUITINGVillejuif, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.